2025 ARVO annual meeting | Salt Lake City, Utah – Chief Scientific Officer, Dr Victor Hernandez, presented a poster on the first gene therapy for the prevention of blindness in Bardet-Biedl Syndrome (BBS) at the 2025 ARVO annual meeting in Salt Lake City, Utah this week. This work describing expression of BBS genes during retinal development has implications for determinng the trial dosage levels.
